Digital Health,
Journal Year:
2024,
Volume and Issue:
10
Published: Jan. 1, 2024
Myriad
digital
health
interventions,
applications,
devices
and
technologies
have,
are,
being
developed
to
help
refine
personalise
medicine
from
the
patient,
healthcare
professional
(HCP),
system
industry
perspectives.
At
a
gathering
of
leaders
in
health,
discussion
included
current
landscape
such
tools
(DHTs),
with
specific
examples
cardiology
respiratory
medicine,
both
benefits
sometime
downfalls
tools.
While
DHTs
can
patients
HCPs
detect
monitor
conditions,
experts
discussed
how
adoption
may
be
hampered
by
issues
as
access
technology;
data
privacy
security
concerns;
technology
integration
into
systems;
cost
reimbursement;
lack
guidelines
regulatory
hurdles.
The
suggested
solutions
issues,
including
wider
availability
‘booths’
local
patient;
easy
understand
use
phone
applications;
patient
HCP
incentives
clear
paths
within
system.
These
should
aid
shared
decision-making
and,
ultimately,
streamline
for
all.
Clinical and Translational Allergy,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Jan. 1, 2024
Abstract
Background
Chronic
spontaneous
urticaria
(CSU)
is
unpredictable
and
can
severely
impair
patients'
quality
of
life.
Patients
with
CSU
need
a
convenient,
user‐friendly
platform
to
complete
patient‐reported
outcome
measures
(PROMs)
on
their
mobile
devices.
CRUSE
®
,
the
Urticaria
Self
Evaluation
app,
aims
address
this
unmet
need.
Methods
was
developed
by
an
international
steering
committee
specialists.
Priorities
for
app
based
recent
findings
in
were
defined
allow
patients
track
record
symptoms
medication
use
over
time
send
photographs.
The
collects
patient
data
such
as
age,
sex,
disease
onset,
triggers,
medication,
characteristics
that
be
sent
securely
physicians,
providing
real‐time
insights.
Additionally,
contains
PROMs
assess
activity
control,
which
are
individualised
profiles
clinical
manifestations.
Results
launched
Germany
March
2022
now
available
free
17
countries.
It
adapted
local
language
displays
country‐specific
list
medications.
English
Ukrainian
versions
worldwide.
From
July
June
2023,
25,710
observations
documented
2540
users;
72.7%
females,
mean
age
39.6
years.
At
baseline,
93.7%
51.3%
users
had
wheals
angioedema,
respectively.
Second‐generation
antihistamines
used
74.0%
days.
Conclusions
initial
from
show
wide
utility
effectively
tracking
paving
way
personalised
management.
The Journal of Allergy and Clinical Immunology In Practice,
Journal Year:
2024,
Volume and Issue:
12(8), P. 2010 - 2016.e7
Published: March 22, 2024
In
the
recent
report
of
Organisation
for
Economic
Co-operation
and
Development
(OECD)
on
Best
Practices
(BPs)
Integrating
Care
to
Prevent
Manage
Chronic
Diseases,
an
app
rhinitis
asthma
(MASK-air
[Mobile
Airways
Sentinel
networK
airway
diseases])
has
been
listed.
The
OECD
is
a
reliable
source
evidence-based
policy
analysis
economic
data
largely
used
by
governments.
It
published
several
BPs
public
health.
On
May
10,
2023,
13
Diseases
in
European
Union.
did
not
cover
all
models
integrated
care;
rather,
it
"focuse(d)
those
that
are
key
strategic
interest
makers."
New
MASK-air
studies
(not
report)
include
equity,
usability
old-age
adults,
impact,
quality
life,
allergen
immunotherapy.
freely
available
iOS
Android
30
countries
recently
introduced
United
States.
BP
represents
model
digitally
enabled,
patient-centered
care
chronic
diseases
using
holistic
approach
shared
decision
making.
Adherence
to
rhinitis
treatment
has
been
insufficiently
assessed.
We
aimed
use
data
from
the
MASK-air
mHealth
app
assess
adherence
oral
antihistamines
(OAH),
intra-nasal
corticosteroids
(INCS)
or
azelastine-fluticasone
in
patients
with
allergic
rhinitis.
included
regular
European
users
self-reported
and
reporting
at
least
1
day
of
OAH,
INCS
azelastine-fluticasone.
assessed
weeks
during
which
answered
questionnaire
on
all
days.
restricted
our
analyses
provided
between
January
June,
encompass
pollen
seasons
across
different
countries.
analysed
symptoms
using
visual
analogue
scales
(VASs)
combined
symptom-medication
score
(CSMS),
performing
stratified
by
weekly
levels.
Medication
was
computed
as
proportion
days
reported
medication
use.
Sensitivity
were
performed
considering
most
missing
months
4
data.
8212
complete
(1361
users).
(use
>
80%
days)
specific
drug
classes
ranged
31.7%
for
38.5%
OAH.
Similar
found
without
asthma,
except
(better
asthma
patients).
VAS
CSMS
levels
increased
no
full
adherence,
INCS.
A
higher
uncontrolled
observed
adherence.
In
weeks,
41.2%
co-medication.
The
sensitivity
displayed
similar
results.
high
MASK-air.
Different
patterns
compared
OAH
that
are
likely
impact
guidelines.
Pediatric Allergy and Immunology,
Journal Year:
2024,
Volume and Issue:
35(2)
Published: Feb. 1, 2024
Abstract
Background
In
allergic
rhinitis
and
asthma,
adolescents
young
adult
patients
are
likely
to
differ
from
older
patients.
We
compared
adolescents,
adults
on
symptoms,
control
levels,
medication
adherence.
Methods
a
cross‐sectional
study
(2015–2022),
we
assessed
European
users
of
the
MASK‐air
mHealth
app
three
age
groups:
(13–18
years),
(18–26
(>26
years).
them
their
reported
asthma
use
adherence
treatment
Allergy
symptoms
were
by
means
visual
analogue
scales
(VASs)
or
combined
symptom‐medication
score
(CSMS),
electronic
daily
for
(e‐DASTHMA).
built
multivariable
regression
models
compare
accounting
potential
differences
in
demographic
characteristics
baseline
severity.
Results
965
adolescent
(15,252
days),
4595
(58,161
15,154
(258,796
days).
Users
all
groups
displayed
similar
models,
not
found
significantly
medication.
These
also
that
lower
VAS
global
allergy,
ocular,
(as
well
as
CSMS)
than
adults.
Conclusions
Adolescents
better
adults,
even
though
levels
observed
across
groups.
results
pave
way
future
studies
understanding
how
diseases.
Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(3), P. 898 - 898
Published: Feb. 4, 2024
Respiratory
allergic
diseases
affect
over
500
million
people
globally
and
pose
a
substantial
burden
in
terms
of
morbidity,
mortality,
healthcare
costs.
Restrictive
factors
such
as
geographical
disparities,
infectious
pandemics,
limitations
resources,
shortages
allergy
specialists
underserved
areas
impede
effective
management.
Telemedicine
encompasses
real-time
visits,
store-and-forward
option
triage,
computer-based
technologies
for
establishing
efficient
doctor-patient
communication.
Recent
advances
digital
technology,
including
designated
applications,
informative
materials,
examination
devices,
wearables,
inhalers,
integrated
platforms,
facilitate
personalized
evidence-based
care
delivery.
The
integration
telemonitoring
respiratory
has
shown
beneficial
effects
on
disease
control,
adherence,
quality
life.
While
the
COVID-19
pandemic
accelerated
adoption
telemedicine,
certain
concerns
regarding
technical
requirements,
platform
quality,
safety,
reimbursement,
regulatory
considerations
remain
unresolved.
artificial
intelligence
(AI)
applications
holds
promise
data
analysis,
pattern
recognition,
treatment
plans.
Striking
balance
between
AI-enabled
insights
human
expertise
is
crucial
optimizing
benefits
telemonitoring.
exhibits
potential
enhancing
patient
delivery,
critical
have
to
be
addressed
order
ensure
successful
into
landscape.
The Journal of Allergy and Clinical Immunology In Practice,
Journal Year:
2024,
Volume and Issue:
12(10), P. 2648 - 2668.e2
Published: July 4, 2024
The
traditional
healthcare
model
is
focused
on
diseases
(medicine
and
natural
science)
does
not
acknowledge
patients'
resources
abilities
to
be
experts
in
their
own
lives
based
lived
experiences.
Improving
safety,
quality,
coordination,
as
well
quality
of
life,
an
important
aim
the
care
patients
with
chronic
conditions.
Person-centered
needs
ensure
that
people's
values
preferences
guide
clinical
decisions.
This
paper
reviews
current
knowledge
develop
(1)
digital
pathways
for
rhinitis
asthma
multimorbidity
(2)
digitally
enabled,
person-centered
care.
